SCHEMBL3017596

SCHEMBL3017596

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cccc(F)c3)CC2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPT P10636 4/20 0.52
USP2 O75604 2/20 0.52
HSD17B10 Q99714 2/20 0.52
RECQL P46063 1/20 0.52
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PKM P14618 1/20 0.44
GBA1 P04062 1/20 0.43
LMNA P02545 5/20 0.43
POLB P06746 2/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 2/20 0.43
TSHR P16473 3/20 0.43
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013485 0.91 MAPT (0.58) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3017934 0.91 MAPT (0.54) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3012668 0.91 MAPT (0.54) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3015005 0.89 MAPT (0.46) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3016080 0.89 MAPT (0.46) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3014141 0.89 GAA (0.51) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3016995 0.88 KMT2A (0.47) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3015038 0.88 HSD17B10 (0.57) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3003954 0.88 MAPT (0.49) GFERMEN1KMT2AMAPTUSP2
SCHEMBL3008981 0.88 ALDH1A1 (0.47) GFERMEN1KMT2AMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GFER 4485/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.